Search research articles
Contact Us
Filters
Showing results (11-20 of 44) with videos related to
Page
of 5
Sort By:
Journal of Surgical Oncology
|
October 30, 2010
Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients
Jean Sebastien Frenel, Christophe Leux, Luc Pouplin, et al.
Gynecologic Oncology
|
December 8, 2018
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, et al.
Frontiers in Medicine
|
August 11, 2015
Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up
Daniela Rusu, Thomas Carlier, Mathilde Colombié, et al.
Annals of Surgical Oncology
|
May 14, 2014
Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study
Jean-François Le Brun, Loic Campion, Dominique Berton-Rigaud, et al.
Plos One
|
August 11, 2011
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment
Nassima Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, et al.
The Oncologist
|
October 10, 2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy
Mario Campone, Dominique Berton-Rigaud, Florence Joly-Lobbedez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors
Isabelle Ray-Coquard, Jubilee Brown, Philipp Harter, et al.
Oncotarget
|
May 1, 2018
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
Norbert Vey, Lionel Karlin, Sophie Sadot-Lebouvier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma
Dominique Berton-Rigaud, Mojgan Devouassoux-Shisheboran, Jonathan A Ledermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 44) with videos related to
Sort By:
Page
of 5
Journal of Surgical Oncology
|
October 30, 2010
Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients
Jean Sebastien Frenel, Christophe Leux, Luc Pouplin, et al.
Gynecologic Oncology
|
December 8, 2018
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, et al.
Frontiers in Medicine
|
August 11, 2015
Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up
Daniela Rusu, Thomas Carlier, Mathilde Colombié, et al.
Annals of Surgical Oncology
|
May 14, 2014
Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study
Jean-François Le Brun, Loic Campion, Dominique Berton-Rigaud, et al.
Plos One
|
August 11, 2011
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment
Nassima Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, et al.
The Oncologist
|
October 10, 2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy
Mario Campone, Dominique Berton-Rigaud, Florence Joly-Lobbedez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors
Isabelle Ray-Coquard, Jubilee Brown, Philipp Harter, et al.
Oncotarget
|
May 1, 2018
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
Norbert Vey, Lionel Karlin, Sophie Sadot-Lebouvier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma
Dominique Berton-Rigaud, Mojgan Devouassoux-Shisheboran, Jonathan A Ledermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2017
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, et al.
Page
of 5